Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

類似資料

• Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
  著者:: Xu, Yankai, 等
  出版事項: (2017)
• Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
  著者:: Chapple, Christopher R., 等
  出版事項: (2016)
• The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial
  著者:: Batista, Jose E., 等
  出版事項: (2015)
• Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
  著者:: Mueller, Elizabeth R., 等
  出版事項: (2019)
• Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada
  著者:: Herschorn, Sender, 等
  出版事項: (2017)